1Patat A, Paty I, Hindmarch I. Pharmacodynamic profile of Zaleplon, a new non-benzodiazcpine hypnotic agent. Hum Psychopharmacol. 2001 ; 16 (5) : 369-392.
2Roehrs T, Rosenthal L, Koshorek G, et al. Effects of zaleplon or triazolam with or without ethanol on human performance. Sleep Med. 2001; 2 (4): 323-332.
3Menzin J, Lang KM, Levy P, et al. A general model of the effects of sleep medications on the risk and cost of motor vehicle accidents and its application to France. Pharmacoeconomics, 2001; 19 (1): 69-78.
4Duke AN, Platt DM, Cook JM, et al. Enhanced sucrose pellet consumption induced by benzodiazepine-type drugs in squirrel monkeys: role of GABAA receptor subtypes. pharmacology (Berl), 2006; 187 (3) : 321-330.
5Pandi-Perumal SR, Verster JC, Kayumov L, et al. Sleep disorders, sleepiness and traffic safety: a public health menace. Braz J Med Biol Res. 2006; 39 (7) : 863-871.
6Danjou P, Paty 1, Fruncillo R, et al. A comparison of the residual effects of zaloplon and zolpidem following administration 5 to 2 h before awakening. Br J Clin Pharmacol. 1999 ; 48 (3) : 367-74.
7Kripke DF. Greater incidence of depression with hypnotic use than with placebo. BMC Psychiatry, 2007; 21: 7-42.
8Sein Anand J, Chodorowski Z, Hajduk A. Acute intoxication with zaleplon-a case report Acute intoxication with zaleplon-a case report. Przegl Lek. 2007; 64 (4-5): 310-311.
9Ancoli-Israel S, Richardson GS, Mangano RM, et al. Long-term use of sedative hypnotics in older patients with insomnia. Sleep Med. 2005; 6 (2): 107-113.
10Rush CR, Frey JM, Grifriths RR. Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl), 1999; 145 (1): 39-51.
